Antares Pharma, Inc.
Medical Devices & Tech
s 13755 First Avenue North
Minneapolis, Minnesota 55441 USA
phone: +1 (763) 475 7700
fax: +1 (763) 476 1009
Symbol AIS
Exchange AMEX
Founded 1979
Employees 27
www.antarespharma.com
Research Sector Medical Devices & Tech
Summary Description
Needle-free injectors for personal use.
Management
Jack E. Stover, President and Chief Executive Officer; Robert F. Apple, Sr. Vice President and CFO; Peter L. Sadowski, Ph.D., Vice President, Devices Group; James E. Hattersley, Vice President, Corporate Business Development; Dario N. R. Carrara, Ph.D., Executive Director, Formulations Group; Michael L. Kasprick, Executive Director, Corporate Business Development
Ownership
Financials Mkt Cap :32


* numbers in thousands

 
Keywords
needle-free, injection, drug delivery, transdermal gels, fast-melt tablets, Diabetes, blood sugar, diabetic, metabolic, insulin, insulin, human growth hormone, contraceptive, osteoarthritis, DrugDelivery

Comment | Printable Version | Nov. 01, 2008
If you work for Antares Pharma, Inc. and want to update this profile, click here

Description
Antares Pharma develops proprietary and specialized drug delivery systems for drugs with active ingredients that have already been FDA-approved. The company's technology platforms include transdermal drug delivery gels, fast-melt oral tablets, disposable mini-needle injection systems, and reusable needle-free injection systems.
Products / Services
The Company's current products include transdermal Advanced Transdermal Delivery (ATD(tm)) gels; fast-melt oral disintegrating tablets (Easy Tec(tm)); disposable minineedle injection systems (Vibex(tm)); and reusable needle-free injection systems (Medi-Jector VISION® and Valeo(tm)).
Technology / Differentiation
Antares Pharma's transdermal drug delivery platform deliver medication with less potential for skin irritation, while avoiding the initial gastrointestinal and liver uptake problems of some orally ingested drugs.
Market / Customers
Antare's device focus is specifically on the market for delivery of self-administered injectable drugs. The largest and most mature segments of this market consist of insulin for patients with diabetes and human growth hormone for children with growth retardation. According to industry sources, the worldwide insulin market is estimated to grow from $7.7 billion in 2005 to $14.6 billion in 2010, of which $2 billion in 2010 is inhaled insulin.
Competitors / Substitutes / Alternatives
Bioject Medical Technologies, Bentley Pharmaceuticals, Aradigm, Cellegy Pharmaceuticals, Cardinal Health, CIMA Laboratories, Laboratoires Besins-Iscovesco, MacroChem Corporation, NexMed, Novavax
Strategy
Antares Pharma key strategies are to validate early technologies/platforms with development, leverage proprietary platforms to develop internal pipeline, out license product rights in larger more mature sectors, commercialize products in niche physician sectors of dermatology,pain, urology, CNS, and womens health, acquire or license complimentary products or technology and market products in niches or seek marketing partners.
Status
Late in 2005 Antares announced their first commercial deal with a subsidiary of Teva Pharmaceuticals for their novel injector device with their drug.


2008-11-21-710